Ohanyan Sona, Buxbaum Chen, Stein Polina, Ringelstein-Harlev Shimrit, Shelly Shahar
Department of Neurology, Rambam Medical Center, Haifa 3655306, Israel.
Department of Neurology, University of Alberta Hospital, Edmonton, AB T6G 2B7, Canada.
J Clin Med. 2024 Aug 13;13(16):4745. doi: 10.3390/jcm13164745.
The incidence of lymphomatous involvement of the central nervous system (CNS) has been increasing in recent years. However, the rarity of the disease has resulted in a scarcity of available data regarding its clinical presentation, natural history, and prognosis. We aimed to investigate the neurological characteristics of uncommon lymphomatous involvements confined to the CNS and to identify key variables that could serve as predictive biomarkers for treatment outcomes. We identified patients presenting with neurological symptoms and diagnosed with CNS-restricted lymphomatous involvement between 2005 and 2023. We identified 44 cases, 93% of which were diagnosed with primary central nervous system lymphoma (PCNSL) and 7% with intravascular lymphoma. The median time from symptom onset to diagnosis was 47 days (range: 6-573 days), with no statistically significant difference between patients older and younger than 60 years ( = 0.22). The median follow-up time was 1144 days (range: 27-3501 days). Cognitive deterioration was the most common presenting symptom, occurring in 19 out of 44 patients (43%). Brain MRI revealed that lobar lesions were the most frequent location of lesions, found in 24 out of 44 patients (55%). By the end of the study period, 30 patients (68%) had died, with a median survival of 666 days (range: 17-3291 days). Death was significantly more common in patients who experienced relapses (p = 0.04; 95% CI: 0.99-0.03), with these patients having a four times higher chance of death (HR = 4.1; 95% CI: 1.01-16.09). The time to diagnosis significantly correlated with survival ( = 0.02; 95% CI: 0.005-0.54), as did the Eastern Cooperative Oncology Group (ECOG) performance status at the last follow-up ( = 0.006; 95% CI: 0.0012-0.62). Patients aged over 60 years did not exhibit a higher likelihood of death ( = 0.19; HR = 2.3; 95% CI: 0.63-8.61); however, the threshold age at diagnosis for the maximally predicted mortality was 64 years (ROC = 0.73; = 0.03). Patients had significant delays in diagnosis, affecting patient outcomes. Cognitive deterioration and lobar lesions were prominent clinical and radiological features. Mortality was notably higher in patients with relapses and those who had a longer time to diagnosis.
近年来,中枢神经系统(CNS)淋巴瘤受累的发生率一直在上升。然而,这种疾病的罕见性导致了关于其临床表现、自然病程和预后的可用数据稀缺。我们旨在研究局限于中枢神经系统的罕见淋巴瘤受累的神经学特征,并确定可作为治疗结果预测生物标志物的关键变量。我们确定了2005年至2023年间出现神经症状并被诊断为中枢神经系统局限淋巴瘤受累的患者。我们确定了44例病例,其中93%被诊断为原发性中枢神经系统淋巴瘤(PCNSL),7%为血管内淋巴瘤。从症状出现到诊断的中位时间为47天(范围:6 - 573天),60岁及以上和60岁以下患者之间无统计学显著差异(P = 0.22)。中位随访时间为1144天(范围:27 - 3501天)。认知功能恶化是最常见的首发症状,44例患者中有19例(43%)出现。脑部MRI显示叶性病变是最常见的病变部位,44例患者中有24例(55%)发现。到研究期结束时,30例患者(68%)死亡,中位生存期为666天(范围:17 - 3291天)。复发患者的死亡明显更常见(P = 0.04;95%置信区间:0.99 - 0.03),这些患者的死亡几率高出四倍(风险比 = 4.1;95%置信区间:1.01 - 16.09)。诊断时间与生存期显著相关(P = 0.02;95%置信区间:0.005 - 0.54),末次随访时的东部肿瘤协作组(ECOG)体能状态也如此(P = 0.006;95%置信区间:0.0012 - 0.62)。60岁以上患者的死亡可能性并未更高(P = 0.19;风险比 = 2.3;95%置信区间:0.63 - 8.61);然而,最大预测死亡率的诊断阈值年龄为64岁(曲线下面积 = 0.73;P = 0.03)。患者诊断存在显著延迟,影响患者预后。认知功能恶化和叶性病变是突出的临床和放射学特征。复发患者和诊断时间较长的患者死亡率明显更高。